Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
- PMID: 39443529
- PMCID: PMC11500384
- DOI: 10.1038/s41598-024-73777-y
Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
Abstract
123I-FP-CIT SPECT enables the detection of presynaptic dopaminergic denervation. It allows to differentiate degenerative parkinsonian syndromes from secondary parkinsonian syndromes or essential tremor, and patients with suspected dementia with Lewy bodies from those with other dementia subtypes. The aim of our study was to evaluate the appropriateness of 123I-FP-CIT SPECT prescriptions, identify prescriber profiles and analyze changes in prescriptions over a decade in the Neurology department of Avicenne University hospital. This retrospective study included all patients who underwent 123I-FP-CIT SPECT between February 2009 and May 2019 (n = 723). Clinical and paraclinical data were compared between three groups based on the relevance of 123I-FP-CIT SPECT prescription: "inappropriate", "uncertain" and "relevant". We showed that inappropriate indications accounted for 37.5% of 123I-FP-CIT SPECT requests. Hospital neurologists and neurologists with mixed practice accounted for 74.1% of 123I-FP-CIT SPECT requests, hospital movement disorders specialists being more likely to prescribe appropriately (67.1%) than hospital non-movement disorders specialists (33.3%). Following the replacement of the neuro-oncology team with a team including movement disorders specialists, the percentage of relevant SPECT 123I-FP-CIT prescriptions rose from 37.5% to 81.0%. These observations suggest that seeking the expertise of a movement disorders specialist would be more relevant than the systematic prescription of 123I-FP-CIT SPECT.
Keywords: 123I-FP-CIT SPECT; Atypical parkinsonian syndromes; Degenerative parkinsonian syndromes; Movement disorders; Parkinson’s disease.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures


Similar articles
-
The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.J Neurol. 2011 Dec;258(12):2147-54. doi: 10.1007/s00415-011-6076-z. Epub 2011 May 6. J Neurol. 2011. PMID: 21547379
-
[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes.J Neuroimaging. 2012 Jul;22(3):225-30. doi: 10.1111/j.1552-6569.2011.00583.x. Epub 2011 Mar 16. J Neuroimaging. 2012. PMID: 21410815 Review.
-
Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.J Neurol. 2012 Feb;259(2):251-60. doi: 10.1007/s00415-011-6163-1. Epub 2011 Jul 13. J Neurol. 2012. PMID: 21750954
-
Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome.J Neurol Sci. 2015 Apr 15;351(1-2):127-132. doi: 10.1016/j.jns.2015.02.051. Epub 2015 Mar 7. J Neurol Sci. 2015. PMID: 25772188
-
[The applicability of 123I-FP-CIT SPECT dopamine transporter imaging in clinical practice].Ideggyogy Sz. 2019 Nov 30;72(11-12):381-388. doi: 10.18071/isz.72.0381. Ideggyogy Sz. 2019. PMID: 31834681 Review. Hungarian.
Cited by
-
The Utilization and Impact of Dopamine Transporter Imaging in Diagnosing Movement Disorders at a Tertiary Care Hospital in Greece.Biomedicines. 2025 Apr 16;13(4):970. doi: 10.3390/biomedicines13040970. Biomedicines. 2025. PMID: 40299648 Free PMC article.
References
-
- Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord.30, 1591–1601 (2015). - PubMed
-
- Postuma, R. B. et al. Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 33, 1601–1608 (2018). - PubMed
-
- Fleury, V., Brindel, P., Nicastro, N. & Burkhard, P. R. Descriptive epidemiology of parkinsonism in the canton of Geneva, Switzerland. Parkinsonism Relat. Disord. 54, 30–39 (2018). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources